The history of Alzheimer's disease (AD) started in 1907, but we needed to wait until the end
of the century to identify the components of pathological hallmarks and genetic subtypes and …

It became clear that dementia progresses very differently, both between and within
individuals. This implies an average trajectory is not informative to individual persons and …

Background Alzheimer's disease (AD) is a highly heterogeneous disease with diverse
trajectories and outcomes observed in clinical populations. Understanding this …

There is an extensive literature relating to factors associated with the development of
Alzheimer's disease (AD), but less is known about factors which may contribute to its …

The aim of this study was to evaluate the effect of cognitive reserve (CR), in progression from
subjective cognitive decline (SCD) to mild cognitive impairment (MCI) and Alzheimer's …

Alzheimer's disease is one of the deadly progressive neurodegenerative diseases among
aged populations. But, the progression of the disease can be reduced by proper treatment of …

Introduction Variability exists in the disease trajectories of Alzheimer's disease (AD) patients.
We performed a genome‐wide association study to examine rate of cognitive decline (ROD) …

Background The prevalence of neurodegenerative diseases is expected to increase over
the next years, therefore, new methods able to prevent and delay cognitive decline are …

Background: More people with cognitive dysfunction and dementia also fall into the category
of high vascular risk, for which aspirin is one of the most frequently used drugs. However …

Amyloid deposits are one of the hallmark pathological lesions of Alzheimer's disease (AD).
They can be visualized by thioflavin-S, silver impregnation, Congo red staining, and …